<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822727</url>
  </required_header>
  <id_info>
    <org_study_id>FCRE-201016</org_study_id>
    <nct_id>NCT04822727</nct_id>
  </id_info>
  <brief_title>AndraTec PMCF Study : Investigating the AndraTec Guidewires,PTA Balloons and Stents in Iliac Disease.</brief_title>
  <official_title>A Prospective Physician-Initiated PMCF Study Investigating the Safety and Clinical Performance of the Lokum L-Quest Guidewire, the Lokum Amplatz Guidewire, the Slider Hydrophilic Nitinol Guidewire, the AltoSa-XL PTA Balloon, the AltoSa-XL Gemini Balloon Catheter, the Optimus XL CoCr Stent and the Optimus CVS PTFE Covered XL Stent for the Endovascular Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Giovanni Torsello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FCRE (Foundation for Cardiovascular Research and Education)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This PMCF study is designed as prospective, multi-center study to collect real-life data.&#xD;
&#xD;
      The rationale of this study is to confirm and support the clinical safety and performance of&#xD;
      the aforementioned products in 200 patients who will undergo an endovascular intervention&#xD;
      within standard-of-care (SOC) where at least 1 of the following devices from AndraTec were&#xD;
      used:&#xD;
&#xD;
      The LOKUM-Quest guidewire, The LOKUM AMPLATZ guidewire, the Slider Hydrophilic Nitinol&#xD;
      Guidewire, the AltoSa-XL PTA balloon, the AltoSa-XL GEMINI PTA Balloon, the OPTIMUS CoCr&#xD;
      Stent , the OPTIMUS-CVS PTFE-Covered stent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Freedom from MACE (Major Adverse Clinical Events) and/or Device related events during the procedure</measure>
    <time_frame>during procedure</time_frame>
    <description>MACE defined as: Death, Myocardial Infarction, Stroke, Emergent surgical revascularization of the target vessel, repeat vascularization of the target vessel, bleeding complication requiring transfusion)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>during procedure</time_frame>
    <description>defined as successfully introduction and deployment of the Lokum L-Quest, and/or the Lokum Amplatz, and/or the Slider Hydrophilic Nitinol Guidewire, and/or the Optimus CoCr Stent, and/or the Optimus PFTE covered BE Stent, and/or the AltoSa-XL-PTA, and/or the AltoSa-XL-Gemini Balloon Catheter according to the respective IFU and without device related deficiencies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>For the Optimus CoCr and Optimus-CVS PTFE-covered stent: Freedom from MACE post-procedure, after 6- and 12-months.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>MACE defined as: Death, Myocardial Infarction, Stroke, Emergent surgical revascularization of the target vessel, repeat vascularization of the target vessel, bleeding complication requiring transfusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For the Optimus CoCr and Optimus-CVS PTFE-covered stent: Freedom from Device-related serious adverse events (SAE's) post-procedure, after 6- and 12-months</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Freedom from Device-Related serious adverse events (SAE's)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Target Lesion Revascularization post-procedure, at 6- and 12-months</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Defined as freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Iliac Artery Disease</condition>
  <condition>Peripheral Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1 or more AndraTec devices (see description for list of devices)</intervention_name>
    <description>1 or more AndraTec devices (Lokum L-Quest guidewire, Lokum Amplatz guidewire, Slider Hydrophilic Nitinol Guidewire, AltoSa-XL PTA Balloon, Alto-Sa-XL Gemini Balloon, Optimus-CoCr stent, Optimus-CVS PTFE covered stent)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with peripheral arterial disease, meeting the in/exclusion criteria and eligible&#xD;
        for treatment with the AndraTec devices, according to the IFU of each device.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Corresponding to the CE-mark indications/contra-indications and according to the current&#xD;
        medical guidelines for minimally invasive peripheral interventions.&#xD;
&#xD;
        Patient is willing to comply with specified follow-up evaluations at the specified times&#xD;
        for the duration of the study (depending on the used device during the procedure) Patient&#xD;
        is &gt;18 years old Patient understands the nature of the procedure and provides written&#xD;
        informed consent, prior to enrolment in the study Patient is eligible for treatment with&#xD;
&#xD;
          -  the Lokum L-Quest guidewire&#xD;
&#xD;
          -  and/or the Lokum Amplatz guidewire&#xD;
&#xD;
          -  and/or the Slider Hydrophilic Nitinol Guidewire&#xD;
&#xD;
          -  and/or the AltoSa-XL PTA balloon&#xD;
&#xD;
          -  and/or the AltoSa-XL Gemini balloon catheter&#xD;
&#xD;
          -  and/or the Optimus-XL CoCr Bare Metal Stent&#xD;
&#xD;
          -  and/or the Optimus-XL CVS PTFE Covered Stent, as described in the IFU for each device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Application in coronary, cerebral arteries and central circulatory system&#xD;
&#xD;
          -  Known contraindication to peripheral arterial and visceral vasculature treatment -&#xD;
             Anatomy or size of vessels that will not allow appropriate usage of the&#xD;
             investigational devices, following IFU of the investigational devices.&#xD;
&#xD;
          -  Known contraindication and/or allergy to (a component of) an investigational device&#xD;
&#xD;
          -  Pregnant women and women with childbearing potential not taking adequate&#xD;
             contraceptives or currently breastfeeding&#xD;
&#xD;
          -  Life expectancy of less than twelve months&#xD;
&#xD;
          -  Any planned surgical intervention/procedure within 30 days of the study procedure&#xD;
&#xD;
          -  Any patient considered to be hemodynamically unstable at onset of procedure&#xD;
&#xD;
          -  Patient is currently participating in another investigational drug or device study&#xD;
             that has not completed the entire follow-up period.&#xD;
&#xD;
        Device-related exclusion criteria (not applicable for guidewire):&#xD;
&#xD;
          -  Known contraindications given in the IFU of Optimus CoCr and Optimus-CVS PTFE- Covered&#xD;
             Balloon-Expandable Stent which includes treatment of renal arteries, aneurysms&#xD;
             adjacent to site of stent implantation and neurovascular treatment&#xD;
&#xD;
          -  Known contraindications given in the IFU of AltoSa-XL-PTA and AltoSa-XL-Gemini Balloon&#xD;
             catheter:&#xD;
&#xD;
               -  patients with a contraindication for anti-platelet/anti-coagulant therapy&#xD;
&#xD;
               -  patients with excessive vessel tortuosity&#xD;
&#xD;
               -  dilatation of in-stent restenosis and highly calcified stenosis&#xD;
&#xD;
               -  patients with perforated vessels evidenced by extravasation of contrast media&#xD;
&#xD;
               -  patients with a known hypersensitivity to nylon&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Torsello, Prof. MD.</last_name>
    <role>Study Director</role>
    <affiliation>Foundation for Cardiovascular Research and Education</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annelena Held, Dr.</last_name>
    <phone>+49 157 85 128 140</phone>
    <email>annelena.held@fcre.eu</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>FCRE (Foundation for Cardiovascular Research and Education)</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Torsello</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

